Crinetics Pharmaceuticals (CRNX)
(Delayed Data from NSDQ)
$53.15 USD
-0.73 (-1.35%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $53.27 +0.12 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Crinetics Pharmaceuticals, Inc. (CRNX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$69.62 | $97.00 | $48.00 | 29.21% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Crinetics Pharmaceuticals, Inc. comes to $69.62. The forecasts range from a low of $48.00 to a high of $97.00. The average price target represents an increase of 29.21% from the last closing price of $53.88.
Analyst Price Targets (13)
Broker Rating
Crinetics Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.15 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.15 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, 12 are Strong Buy, representing 92.31% of all recommendations. A month ago, Strong Buy represented 92.31%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 12 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/16/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
8/8/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
8/8/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
6/28/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
6/4/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
6/4/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/23/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Strong Buy |
5/10/2024 | LifeSci Capital | Cory Jubinville | Strong Buy | Strong Buy |
3/6/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
2/12/2024 | Evercore Partners | Gavin Clark-Gartner | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.15 |
ABR (Last week) | 1.15 |
# of Recs in ABR | 13 |
Average Target Price | $69.62 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -0.91 |
CRNX FAQs
Crinetics Pharmaceuticals, Inc. (CRNX) currently has an average brokerage recommendation (ABR) of 1.15 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms.
The average price target for Crinetics Pharmaceuticals, Inc. (CRNX) is $69.62. The current on short-term price targets is based on 9 reports.
The forecasts for Crinetics Pharmaceuticals, Inc. (CRNX) range from a low of $48 to a high of $97. The average price target represents a increase of $30.99 from the last closing price of $53.15.
The current UPSIDE for Crinetics Pharmaceuticals, Inc. (CRNX) is 30.99%
Based on short-term price targets offered by 13 analysts, the average price target for Crinetics Pharmaceuticals, Inc. comes to $69.62. The forecasts range from a low of $48.00 to a high of $97.00. The average price target represents an increase of 29.21% from the last closing price of $53.88.